An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their mutation type, is being tested in human trials in the UK and Europe.
Long COVID affects 38% of emergency patients with persistent symptoms
Researchers found that post-COVID-19 condition (PCC) symptoms persist in a significant number of both SARS-CoV-2 positive and negative emergency department patients, highlighting the non-specific nature